<div id="readability-page-1"><p><span>NeuroPace (NASDAQ:NPCE - Get Free Report)</span> had its price objective lifted by JPMorgan Chase &amp; Co.  from $18.00 to $20.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s price target suggests a potential upside of 20.96% from the stock's current price.</p><p>Several other equities research analysts have also recently commented on NPCE. Leerink Partners  reissued an &#34;outperform&#34; rating and issued a $19.00 price target on shares of NeuroPace in a research note on Wednesday, November 5th. Zacks Research downgraded shares of NeuroPace from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, August 13th. UBS Group  reiterated a &#34;buy&#34; rating and issued a $18.00 price objective on shares of NeuroPace in a report on Tuesday. Wells Fargo &amp; Company raised their target price on NeuroPace from $15.00 to $16.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, November 5th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of NeuroPace in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $17.83.</p><p><b>Read Our Latest Research Report on NeuroPace</b></p><h2>NeuroPace Stock Up 1.6%</h2><p>Shares of NASDAQ NPCE traded up $0.27 during mid-day trading on Wednesday, reaching $16.54. The company had a trading volume of 43,414 shares, compared to its average volume of 250,078. The company has a debt-to-equity ratio of 3.17, a quick ratio of 3.94 and a current ratio of 4.86. The company has a market capitalization of $550.78 million, a price-to-earnings ratio of -21.72 and a beta of 1.85. The stock has a fifty day moving average of $12.63 and a two-hundred day moving average of $11.04. NeuroPace has a 12-month low of $7.56 and a 12-month high of $18.98. </p><p>NeuroPace (NASDAQ:NPCE - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 136.60%. The company had revenue of $27.35 million during the quarter, compared to the consensus estimate of $24.64 million.  As a group, equities research analysts expect that  NeuroPace will post -1 EPS for the current year. </p><h2>Institutional Investors Weigh In On NeuroPace</h2><p>A number of institutional investors have recently added to or reduced their stakes in NPCE. Ameritas Investment Partners Inc. raised its stake in  NeuroPace by 83.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock worth $27,000 after acquiring an additional 1,118 shares in the last quarter.  Legal &amp; General Group Plc increased its holdings in  NeuroPace by 86.0% during the 2nd quarter. Legal &amp; General Group Plc now owns 2,679 shares of the company's stock valued at $30,000 after purchasing an additional 1,239 shares in the last quarter.  GSA Capital Partners LLP boosted its stake in  NeuroPace by 2.5% in the third quarter. GSA Capital Partners LLP now owns 54,536 shares of the company's stock worth $562,000 after purchasing an additional 1,323 shares in the last quarter.  Quarry LP grew its holdings in shares of  NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company's stock worth $40,000 after purchasing an additional 1,872 shares during the last quarter.  Finally, Rhumbline Advisers increased its stake in shares of  NeuroPace by 15.2% in the first quarter. Rhumbline Advisers now owns 17,227 shares of the company's stock valued at $212,000 after buying an additional 2,267 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds. </p><h2>About NeuroPace</h2> (Get Free Report)<p>NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.</p><h2>See Also</h2><ul><li>Five stocks we like better than NeuroPace</li><li>How to Read Stock Charts for Beginners</li><li>Apple Stock Could Surge on Record iPhone Sales and Bold AI Strategy</li><li>The 3 Best Fintech Stocks to Buy Now</li><li>Dividend Growth Is Heating Up: 3 Stocks With Steady Payout Gains</li><li>Why Are Stock Sectors Important to Successful Investing?</li><li>Why AutoZone’s Stock Drop Could Be a Golden Buying Opportunity</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlBDRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlBDRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in NeuroPace Right Now?</h2><p>Before you consider NeuroPace, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.</p><p>While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NPCE

<p>JPMorgan Chase & Co. raised NeuroPace's price target from $18.00 to $20.00, maintaining an "overweight" rating, suggesting a 20.96% upside. Other analysts have mixed ratings, with a consensus "Moderate Buy" and a $17.83 price target. NeuroPace's stock rose 1.6% to $16.54, with a market cap of $550.78 million. Institutional investors are actively adjusting their stakes in the company.</p>

JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price